Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.53 |
| ▸ | OXTR | P30559 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387478 | 0.94 | HRH3 (0.51) | HRH3OXTRSLC6A4CHRNA7ITGB3 | |
| SCHEMBL3386743 | 0.91 | DRD2 (0.48) | HRH3OXTRSLC6A4 | |
| SCHEMBL3387643 | 0.86 | HRH3 (0.51) | HRH3OXTRSLC6A4ITGB3ITGA2B | |
| SCHEMBL3391353 | 0.85 | PDK1 (0.47) | HRH3OXTRSLC6A4 | |
| SCHEMBL3388080 | 0.84 | HRH3 (0.56) | HRH3CHRNA7 | |
| SCHEMBL4351007 | 0.83 | HRH3 (0.49) | HRH3OXTRSLC6A4CHRNA7 | |
| SCHEMBL3391314 | 0.82 | OXTR (0.52) | HRH3OXTR | |
| SCHEMBL3387602 | 0.82 | HRH3 (0.54) | HRH3CHRNA7 | |
| SCHEMBL18941317 | 0.81 | OXTR (0.49) | HRH3OXTRITGB3ITGA2B | |
| SCHEMBL3389497 | 0.81 | HRH3 (0.42) | HRH3OXTRSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029534-B1 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| CN-101443311-A | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | CN | disclosed |
| US-7432255-B2 | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HRH4, HRH2, HRH3 | HRH3 3/4885OXTR 368/4885SLC6A4 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.